


PHARMACEUTICAL 2021

MOLECULIN

Moleculin Biotech Inc. Rank 240 of 402





PHARMACEUTICAL 2021

Moleculin Biotech Inc. Rank 240 of 402



The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Moleculin Biotech Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 66%, being 18% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	17,198
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,920
Liabilities, Non-Current	159
Other Assets	11,350
Other Compr. Net Income	34
Other Expenses	-2,146
Other Liabilities	8,192
Other Net Income	41
Other Revenues	0
Property and Equipment	483
Research and Development	12,757
Selling, General and Administrative Expense	6,785

Output Variable	Value in 1000 USD
Assets	29,031
Liabilities	11,271
Expenses	17,396
Revenues	0
Stockholders Equity	17,760
Net Income	-17,355
Comprehensive Net Income	-17,338
Economic Capital Ratio	66%

